Botanical name
Eleutherococcus senticosus (Rupr. & Maxim.) Maxim.
Family
Araliaceae
Common name
Eleuthero, Russian root, Devil's shrub, Devil’s bush, Eleuthero ginseng
Information about the plant
The main distribution area of Siberian ginseng is the boreal coniferous forests of Eastern Siberia (the taiga). It extends east to Japan and Sakhalin, south to South Korea, and to the northern provinces of China. The name ‘Siberian ginseng’ suggests that the plant is used medicinally in the same way as (Korean) ginseng (Panax ginseng C.A. Meyer). In the mountainous northeastern provinces of China, another native medicinally used ginseng is found: Chinese ginseng (also notoginseng, Panax pseudo-ginseng Wall.). Details on this are described in the monograph ‘Ginseng’.
The underground parts of Siberian ginseng available on the market are referred to as ‘taiga root’. The specific epithet senticosus (Latin for ‘abundant in thorns or spines’) refers to the spiny bristles that protrude diagonally downwards from the branches of this shrub, which can grow up to 3 m tall. The petioles of the five-lobed, finely serrated leaves are also densely covered with spines. The blue-violet (male and female) and yellow (female) flowers grow in umbels. The female flowers develop into black berries.
Medicinally used parts of plants (herbal drug)
The dried underground parts consisting of the rhizomes and roots are used. The herbal drug is called Siberian ginseng.
For a long time, only extracts of the herbal drug were commercially available, since the export of the drug was banned during the Soviet period. Consequently, there was a long-standing reliance on imports from China and Korea, but today Russian products are also on the market.
For ‘Korean ginseng (Ginseng radix)’, see the monograph ‘Ginseng’.
Constituents of the herbal drug
Siberian ginseng has a very diverse range of secondary metabolites: lignans, hydroxycoumarins, triterpene saponins, steroidal glycosides, phenylacrylic derivatives, and polysaccharides. Analogous to chemically uniform ginsenosides contained in the roots of Korean ginseng, the ingredients of Siberian ginseng have also been referred to as "eleutherosides". This term is best avoided because it does not come from a uniform group of substances.
Quality of the drug
The quality of Siberian ginseng (Eleutherococci radix) is specified in the European Pharmacopoeia (Ph. Eur.).
Medical applications
Recognised medical use
The HMPC has classified Siberian ginseng as a traditional herbal medicinal product (see ‘Traditional use’).
ESCOP: For declining mental and physical capacity, such as weakness, exhaustion, fatigue, and reduced ability to concentrate, as well as during convalescence.
Indications supported by clinical trials (authorization): To maintain and stimulate the body’s physical defenses, particularly in cases of exceptional physical, emotional, and mental stress.
Traditional use
Siberian ginseng has been classified by the HMPC as a traditional herbal medicinal product (Article 16a of Directive 2001/83/EC). Based upon long-standing use, Siberian ginseng can be taken internally to alleviate symptoms of asthenia (abnormal loss of strength and energy), such as tiredness and weakness.
Herbal drug preparations in finished dosage forms
- Dry extracts in capsules and tablets
- Liquid extract in drops
Dosage
Finished medicinal products: See patient information leaflet.
Tea: The recommended daily dose is 0.5 to 4 g of Siberian ginseng, which can be taken all at once or divided into three portions throughout the day. However, as only extracts were permitted to be sold for a long time, the use of the herbal drug to prepare a tea has not been established.
Preparation of a tea
Pour approximately 150 mL of boiling water over 0.5 to 4 g of finely chopped or finely ground Siberian ginseng and strain after 10 to 15 minutes.
Notes
There are currently no studies available on the safety of using Siberian ginseng during pregnancy and lactation. Use in children under 12 years of age is not recommended due to a lack of evidence.
Side effects
Insomnia, irritability, palpitation, or headaches may occasionally occur.
Interactions
None known.
References
Herbal drug monographs
HMPC (2014), ESCOP (2003), WHO Vol. 2
Further literature
Commentary on the European Pharmacopoeia (taiga root, No. 1419).


